When was BioCryst founded and when did the company go public?
BioCryst was founded in 1986. BioCryst completed its Initial Public Offering in March 1994, raising approximately $14.6 million. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.
Who are the management team members?
BioCryst's senior management team is composed of Jon P. Stonehouse, President and Chief Executive Officer; Stuart Grant, Senior Vice President and Chief Financial Officer, J. Claude Bennett, M.D., Chief Operating Officer; W. James Alexander, M.D., M.P.H., Senior Vice President Clinical Operations and Chief Medical Officer; David S. McCullough, Vice President Strategic Planning and Commercialization, Michael A. Darwin, Vice President Finance; Jonathan M. Nugent, Vice President Corporate Communication; and Yarlagadda S. Babu, Ph.D., Vice President, Drug Discovery. Full biographies of the management team are available by clicking here.
What is BioCryst's current financial condition?
Please refer to the Company's most recent filings with the Securities and Exchange Commission on Forms 10-Q/10-K for the latest published financial information.
When does BioCryst's fiscal year end?
BioCryst's fiscal year ends December 31st.
When are BioCryst's quarterly earnings announcements?
BioCryst releases quarterly earnings and hosts a conference call following the end of each quarter. You may visit our Investor Relations section and submit your email to receive future BioCryst press releases announcing these calls and other events.
How many employees make up the company and where is BioCryst located?
BioCryst currently employs approximately 104 people, of whom 75 are engaged in research and development. The Company has locations in Birmingham, Alabama and Cary, North Carolina.
What exactly does BioCryst do?
BioCryst is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, autoimmune diseases and viral infections. BioCryst's scientists use their understanding of the enzyme families involved in each of these disease areas to enhance the development of product candidates.
What diseases does BioCryst aim to treat?
BioCryst's current areas of focus are primarily on oncology, autoimmune diseases, and viral infections, including seasonal and life threatening influenza.
What is BioCryst's business strategy?
Our business strategy is to increase the value of our drug candidate portfolio. We believe this is best achieved by retaining full product rights to drug product candidates within specialty markets, while relying on collaborative arrangements with third parties for drug product candidates within larger markets or outside our area of expertise. Potential third party alliances could include preclinical development, clinical development, regulatory approval, marketing, sales and distribution of our drug product candidates.
Which compound is furthest along in BioCryst's pipeline?
BioCryst's has several drug candidates in clinical trials. Peramivir is a neuraminidase inhibitor designed for the treatement of influenza. This product is currently in Phase II clinical development with two formulations, intravenous and intramuscular.
Forodesine hydrochloride (BCX-1777, or forodesine HCl), is a purine nucleoside phosphorylase (PNP) inhibitor designed to treat T-lymphocyte mediated disorders. This product is currently in a pivotal trial for the treatment of patients with cutaneous T-cell lymphoma (CTCL). This trial is being conducted under a Special Protocol Assessment from the FDA, which began enrolling patients during the fourth quarter 2007.
BCX-4208 is a second generation PNP inhibitor that we licensed to Roche in 2005 for the treatment of autoimmune diseases and for the prevention of acute rejection in transplantation. Roche initiated a Phase IIa trial during the third quarter of 2007 for patients with moderate to severe psoriasis.
Who are BioCryst's partners?
We currently have partnerships for our three drug candidates in clinical trials. Below is a summary of these partnerships.
- Mundipharma International Holdings, Ltd. for the development and commercialization of Fodosine™ in Europe, Asia, Australia and certain neighboring countries
- Roche for the worldwide development and commercialization of BCX-4208 in autoimmune diseases and acute transplant rejection
- Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan and Korea, respectively.
In January 2007, the U.S. Department of Health and Human Services awarded the Company a $102.6 million, four year contract for the advanced development of peramivir. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other U.S. product approval requirements.
BioCryst currently has collaborations with leading academic organizations including The University of Alabama at Birmingham, Emory University, Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd., New Zealand.
Are you seeking additional partners for your programs?
Our strategy is to increase the value of our drug candidate portfolio and we will consider additional partnerships if we believe they will enhance our ability to fulfill this strategy.
How do I sign up to receive press releases automatically from BioCryst?
You may visit our Investor Relations section and submit your email to receive future BioCryst press releases.
Which research analysts currently follow BioCryst?
For a list of analysts following our progress, please click here.
When is BioCryst's annual meeting and how can I attend?
BioCryst's annual meeting is usually held at The Harbert Center, 2019 Fourth Avenue North, Birmingham, Alabama during May. Please refer to our proxy filing with the SEC for the exact date, time and location.
How do I obtain copies of BioCryst's annual report and contact BioCryst's management team?
Visit the Information Request page to submit your mailing and contact details.
What career opportunities are open at BioCryst and how may I submit my resume?
BioCryst offers a competitive salary and excellent benefits package. For current positions open, please visit our "Career Opportunities" page. All resumes may be submitted with salary requirements to our Human Resource Executive at: BioCryst Pharmaceuticals, Inc., 2190 Parkway Lake Drive, Birmingham, AL 35244 or via e-mail at HumanResources@biocryst.com.
How do I purchase stock in BioCryst?
Contact your local financial representative.
Who is BioCryst's transfer agent?
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
718-921-8247
What is BioCryst's contact information?
Birmingham, Alabama Cary, North Carolina
(205) 444-4600 (919) 859-1302
2190 Parkway Lake Drive 2425 Kildaire Farm Road, Suite 106
Birmingham, AL 35244 Cary, NC 27518
BioCryst's hours of operation are 8-5 CT in the Birmingham office and 8-5 ET in the Cary office.